

The attention on gender in studies on the treatment of hypertension: was it enough?

Enrico Strocchi¹, Laura Baffoni², Alessio Bragagni¹, Mario Soldati¹, Claudio Borghi¹

¹University of Bologna, Italy; ²Infermi Hospital, Rimini, Italy

Received 23 May 2020; accepted 15 October 2020

Summary. Hypertension is an important cardiovascular risk factor, and its treatment is undoubtedly effective in reducing the incidence of cardiovascular and renal events in both sexes, as also reaffirmed by the most recent ESC-ESH guidelines. Our knowledge of the hypertension therapy derives from the evidence generated by a large number of controlled clinical studies carried out over the last decades; however, the authors of these studies did not always evaluate the results obtained separately for males and females. After examining the major controlled clinical studies in the field of hypertension therapy, mentioned in the guidelines, our study found that the analysis of the results had taken account of sex in 21 out of 33 cases only. The most recent meta-analyses – which in some cases concern hundreds of thousands of subjects – were then evaluated, noticing that only in a small minority of cases did the analysis of the results take sex into consideration as a variable; significant problems, such as the treatment of hypertension in the elderly or the pressure levels to be reached with treatment, have never been evaluated from a gender perspective. The study does not demonstrate the existence of gender differences, because this was not its objective, but from an extensive analysis of the literature it concludes that the existence of possible gender differences in the context of high blood pressure therapy is not being sufficiently investigated yet.

Key words. Hypertension, gender medicine, guidelines, controlled clinical trials, meta-analysis.

Attenzione al genere negli studi sul trattamento dell'ipertensione: è sufficiente?

Riassunto. L'ipertensione è un importante fattore di rischio cardiovascolare e il suo trattamento è senza dubbio efficace per ridurre l'incidenza di eventi cardiovascolari e renali in ambedue i sessi, come riaffermato anche dalle più recenti linee guida ESC-ESH. Le nostre conoscenze sulla terapia dell'ipertensione derivano dalle evidenze generate da un ampio numero di studi clinici controllati effettuati negli ultimi decenni; tuttavia gli autori di questi studi non sempre hanno valutato i risultati ottenuti separatamente per maschi e femmine. Questo studio ha preso in esame i più importanti studi clinici controllati nell'ambito della terapia dell'ipertensione, citati nelle linee guida, riscontrando che l'analisi dei risultati aveva tenuto conto del sesso solo in 21 casi su 33. Sono state poi valutate le più recenti metanalisi, che in qualche caso riguardano centinaia di migliaia di soggetti, rilevando come

solo in una esigua minoranza di casi l'analisi dei risultati abbia preso in considerazione il sesso come una variabile; problematiche significative come la terapia dell'ipertensione nell'anziano o i livelli pressori da raggiungere con il trattamento non sono mai state valutate in un'ottica di genere. Lo studio non dimostra l'esistenza di differenze di genere perché questo non era il suo obiettivo, ma da una ampia analisi della letteratura conclude che l'esistenza di possibili differenze di genere nell'ambito della terapia dell'ipertensione arteriosa non è stata ancora sufficientemente indagata.

Parole chiave. Ipertensione, medicina di genere, linee guida, studi clinici controllati, metanalisi.

Introduction

High blood pressure is both an important risk factor for cardiovascular disease and, considering its high prevalence, the leading cause of morbidity and mortality worldwide.^{1,2} Its prevalence increases with age and, while in youth it is greater in the male sex, in the elderly the difference is canceled, or even reversed.³ Although our knowledge has increased in the last 50 years, and many effective and well tolerated drugs have become available, control of high blood pressure remains partial, and therefore many of the benefits that could derive from optimal blood pressure control are lost.⁴ Indeed, the effectiveness of the reduction of blood pressure values is widely documented,⁵ as also reaffirmed by the most recent guidelines, jointly issued by the European Society for Hypertension (ESH) and the European Society of Cardiology (ESC),⁶ which in paragraph 7.1 state: "Meta-analyses of RCTs including several hundred thousand patients have shown that a 10 mmHg reduction in SBP or a 5mmHg reduction in DBP is associated with significant reductions in all major CV events by 20%, all-cause mortality by 10-15%, stroke by 35%, coronary events by 20%, and heart failure by 40%. These relative risk reductions are consistent, irrespective of baseline BP within the hypertensive range, the level of CV risk, comorbidities (eg., diabetes and CKD), age, sex, and ethnicity." Therefore, the guidelines for the treatment of arterial hypertension that constitute the reference text for those involved in the management of patients with arterial hypertension

make no gender distinction. While considering this statement widely acceptable, the purpose of this work was to verify whether the evidences on which the guidelines are based are comparable for both sexes, and whether enough attention has been paid to any possible gender difference in the results of the clinical trials.

Materials and methods

Published records of all randomized clinical trials with at least 1,000 patients, cited by the 2018 ESH-ESC guidelines and regarding hypertension treatment (both non-pharmacological and pharmacological), were collected and screened, with the aim of looking for the total number of patients enrolled and the proportion of females; the statistical analysis and the results were assessed, in order to find out whether sex was considered for subgroup analyses and whether separate results for males and females were reported. When this data was not available in the main publication of the study results, Pub-Med was checked for secondary publications over the following years pertaining to subgroup analyses. Pub-Med was also checked to collect the most important meta-analysis on hypertension treatment, published after the meta-analysis of Turnbull, that was dedicated to gender differences.⁷ For these meta-analyses, we looked for the number of females included, and checked whether the results were reported separately for males and females.

Results

The 33 controlled clinical trials with >1,000 subjects mentioned by the 2018 ESH-ESC guidelines are reported in chronological order in Table 1. Overall, they included 305,249 patients; females were 135,478 (44,38%). Only eleven studies reported the results according to gender in the main paper, but other 7 did it in a subsequent publication devoted to planned subgroup analysis; 3 other trials stated in the main paper to have performed a subgroup analysis for gender, without finding any significant differences among the groups. Studies that did not perform a separate analysis of the results included 77,939 patients (25,5% of the total), and females were well represented (49.2%).

The most relevant meta-analyses are reported in Table 2.

Discussion

Until a few decades ago, medical research and the resulting evidence did not take gender differences into account; only in the last decades, with the development

of gender medicine, physicians became aware of the fact that the personalization of treatments required a special attention to the gender differences that had already been found in numerous other areas. Before even considering any gender differences, it is important to evaluate whether the evidence available to date was collected with studies where males and females were equally represented, and whether the results were assessed separately. High blood pressure is the most common cardiovascular risk factor and its control hasn't been fully achieved yet. Studies show the existence of gender differences (regarding awareness, the percentage of patients treated and well-controlled, and the type of drugs most frequently prescribed) that can only be partially justified. The guidelines state without hesitation that the treatment of hypertension is effective in reducing cardiovascular events, regardless of gender. This study sought to evaluate gender equality among the evidence available in the literature in support of this claim. Given the huge amount of controlled clinical studies relating to the treatment of hypertension in the literature, we chose to refer to those mentioned in the ESH-ESC guidelines of 2018, in the belief that they represent the state of the art; consequently the 33 studies thus identified can be considered as the most representative of the available evidence. There are wide differences in the proportion of females included in the various studies (from 23.4 to 66.8%): the average is 44.38%, a value which – had the prevalence in the population been respected – would have been slightly over 50%. However, if this can somehow be accepted, much more serious is the fact that – even taking into account the secondary publications and the declaration of having performed a subgroup analysis (even in the absence of the results) – only 21 out of 33 studies considered the two sexes separately. Therefore the results in 1/4 of all the patients studied were not analyzed separately for sexes, even though males and females were equally represented. However, it must be recognized that subgroup analysis may not always be feasible and, above all, the inevitable reduction in the events observed within each subgroup can lead to statistically insignificant and/or spurious results. This problem can be overcome, at least partially, with meta-analyses which, combining the data of numerous homogeneous studies, can reach populations large enough to allow a statistically correct evaluation even for subgroups. In 1997, Gueyffier, on behalf of the INDANA group,⁴⁸ performed the first meta-analysis of data with the aim of comparing the effects of antihypertensive treatment in males and females; they gathered the individual data of 7 trials conducted between 1972 and 1990 in 20,802 females and 19,975 males. Their conclusions were that, in terms of relative risk reduction, there were no differences between females and males but, since absolute risk reduction was dependent on untreated risk, for some end-points the

Table 1. Most relevant controlled clinical trials regarding hypertension treatment

Study (year)	Total no. of patients	Males no.	Females no.	Females (%)	Separate results	Subgroup analysis by sex
SHEP (1991) ⁸	4,736	2,046	2,690	56.8	Yes	
STOP (1991) ⁹	1,627	608	1,019	62.6	Yes	
SYST-EUR (1997) ¹⁰	4,695	1,557	3,138	66.8	No	No
UKPDS 38 (1998) ¹¹	1,148	637	511	44.5	No	No
HOT (1998) ¹²	18,790	9,960	8,830	47.0	No	Yes ^{*13}
CAPP (1999) ¹⁴	10,985	5,874	5,111	46.5	No	No
STOP-2 (1999) ¹⁵	6,614	2,196	4,418	66.8	No	No
INSIGHT (2000) ¹⁶	6,321	2,929	3,392	53.7	No	No
NORDIL (2000) ¹⁷	10,881	5,290	5,591	51.4	No	Yes ^{*18}
SYST-CHINA (2000) ¹⁹	2,394	1,541	853	35.6	Yes	
PROGRESS (2001) ²⁰	6,105	4,253	1,852	30.3	No	Yes ^{*21}
ALLHAT (2002) ²²	33,357	17,719	15,638	46.9	Yes	
ELSA (2002) ²³	2,334	1,279	1,055	45.2	No	Yes
LIFE (2002) ²⁴	9,193	4,230	4,963	54.0	No	Yes ^{*25}
INVEST (2003) ²⁶	22,576	10,806	11,770	52.1	Yes	
SCOPE (2003) ²⁷	4,964	1,780	3,184	64.1	No	Yes ^{*28}
VALUE (2004) ²⁹	15,245	8,777	6,468	42.4	No	Yes ^{*30}
ASCOT-BPLA (2005) ³¹	19,257	14,742	4,515	23.4	Yes	
CONVINCE (2005) ³²	16,602	7,375	9,227	55.6	No	No
FEVER (2005) ³³	9,711	5,920	3,791	39.0	No	No
CAFÉ (2006) ³⁴	2,199	1,802	397	18.0	No	Yes
ADVANCE (2007) ³⁵	11,140	6,405	4,735	42.5	Yes	
ONTARGET (2008) ³⁶	25,620	18,789	6,831	26.7	Yes	
ACCOMPLISH (2008) ³⁷	11,506	6,963	4,542	39.5	Yes	
HYVET (2008) ³⁸	3845	1,519	2,326	60.5	No	Yes
ACCORD (2010) ³⁹	4,733	2,475	2,258	47.7	No	Yes ^{*40}
COPE (2011) ⁴¹	3,293	1,669	1,624	49.3	No	
SCAST (2011) ⁴²	2,029	1,176	853	42.0	No	No
ALTITUDE (2012) ⁴³	8,561	5,826	2,735	31.9	No	No
INTERACT 2 (2013) ⁴⁴	2,839	1,780	1,059	37.3	No	No
PREDIMED (2013) ⁴⁵	7,447	3,165	4,282	57.5	Yes	
COLM (2015) ⁴⁶	5,141	2,653	2,488	48.4	No	No
SPRINT (2015) ⁴⁷	9,361	6,029	3,332	35.6	Yes	

*Separate results were reported in a subsequent paper.

Table 2. Most relevant meta-analyses

Author (year)	Purpose	Total no. of patients	Females no. (%)	Gender subgroup analysis
Gueyffier (1997) ⁴⁸	Efficacy of treatment in males and females	407,77	20,802 (51.0)	Yes
Turnbull (2008) ⁷	Sex differences in drug efficacy	190,617	87,349 (45.8)	Yes
Law (2009) ⁴⁹	Efficacy of drug treatment	464,164	?	No
Fagard (2009) ⁵⁰	LVH regression	6,001	?	No
Briasoulis (2014) ⁵¹	Efficacy of treatment in patients >65 yrs	114,854	?	No
Thomopoulos (2014) ⁵²⁻⁵⁴	Efficacy	245,885	?	No
	Efficacy at different BP levels	127,929	?	No
	Efficacy at different CV risk	245,870	?	No
Thomopoulos (2015) ^{55, 56}	Different drugs effects	195,267	?	No
	Head to head comparisons	247,006	?	No
Xie (2016) ⁵⁷	Less vs more and renal disease	44,989	?	No
Brunstrom (2016) ⁵⁸	Efficacy of antihypertensive treatment in diabetics	73,738	?	No
Ettehad (2016) ⁵⁹	BP targets	613,815	?	No
Thomopoulos (2016) ⁶⁰⁻⁶³	Prevention of heart failure	146,810	?	No
	More intense vs less intense treatment	52,235	?	No
	Outcome reductions vs discontinuation due to AE	255,970	?	No
	Discontinuation due to AE with different drugs	147,788	?	No
Bangalore (2017) ⁶⁴	Blood pressure targets	55,163	?	No
Giorgini (2017) ⁶⁵	Sex differences in outcomes with treatment	100,995	42,886 (42.5)	Yes
Weiss (2017) ⁶⁶	Efficacy of treatment in patients >60 yrs	81,395	?	No
Thomopoulos (2017) ⁶⁷⁻⁶⁹	Differences in diabetics	253,125	?	No
	Outcome reductions with lower BP targets	260,210	?	No
	Effects of treatment in patients with high-normal BP	47,991	?	No
Brunstrom (2018) ⁷⁰	Efficacy of treatment	306,273	122,203 (39.9)	Yes (declared)
Karmali (2018) ⁷¹	Efficacy of treatment/CV risk	47,872	21,912 (46.0)	No
Thomopoulos (2018) ^{72,73}	Efficacy of treatment in older vs younger patients	210,558	?	No
	Efficacy of different drugs in older and younger patients	349,726	?	No
Murad (2019) ⁷⁴	Efficacy of treatment >65 yrs	42,134	?	No

BP: blood pressure; CV: cardiovascular; AE: adverse event.

benefit of the treatment in females was not statistically significant. Another important meta-analysis was published by Turnbull et al. in 2008;⁷ the aims of these general analyses were to quantify the effects of blood pressure-lowering treatment in each sex, and to determine if there were important differences in the proportional benefits of the treatment between males and females. They included 31 randomized trials with 103,268 males and 87,349 females, and concluded that all the blood pressure lowering regimens studied generally provided a similar protection against major cardiovascular events in males and females, and that the differences in

cardiovascular risks between the sexes are unlikely to reflect any differences in the response to blood pressure-lowering treatments.

However, Turnbull's meta-analysis⁷ focused on evaluating the effectiveness of individual classes of drugs in the two sexes, while in the following years the interest of research has focused on the effectiveness of combination drugs, on the levels of pressure to be treated and to be achieved, on the differential aspects of therapy, particularly in subgroups and especially the elderly. Unfortunately, most of the subsequent meta-analysis did not investigate separately males and females.

Only Giorgini's meta-analysis⁶⁵ investigated the existence of gender differences in the efficacy of antihypertensive therapy in the 10 studies out of the 64 identified (only 15%) that reported the results separately for males and females, and found an increased residual risk of cardiovascular events in males (RR = 1.25), mainly due to the higher cardiovascular risk at baseline. In his meta-analysis,⁷⁰ which included 74 controlled clinical studies, for a total of 306,273 subjects, Brunstrom doesn't show the results for males and females separately, but states to have considered sex among the covariates, and that this did not entail significant differences in the results achieved, which confirmed the efficacy of the treatment when systolic blood pressure (BP) is >140 mmHg, while for lower values a reduction in events was demonstrable only in a subgroup with previous coronary artery disease.

All the other meta-analyses do not take into consideration the results for males and females separately (they do not even report the total number of males/females enrolled in the studies considered!), and therefore for significant questions – such as the effectiveness of the treatment also in the elderly or the goal of systolic BP to be achieved with therapy – we cannot know if there could be any gender differences.

With regard to the latter, the SPRINT study⁴⁷ played a decisive role in lowering the target BP to be achieved; here, it is not appropriate to analyze the controversial aspects of the study and its possible downsides, but it is worth pointing out that, due to the small number and

the early interruption of the study, in the females' subgroup a statistically significant difference was not reached, and therefore – based on this study – the efficacy of a lower reduction in BP is not demonstrated in females. It would therefore have been helpful if the meta-analyses that dealt with this problem had considered the two sexes separately.

Even the long series of meta-analyses conducted with great scientific rigor by Thomopoulos, Mancia and Zanchetti, published in 14 papers between 2014 and 2018^{52-56,60-63,67-69,72,73} and addressing different aspects of hypertension treatment, do not consider gender as a possible variable. In 2016 Muiesan et al.⁷⁵ – after describing the differences between the two sexes in the epidemiology of hypertension, in the use of the different classes of drugs and in the proportion of patients aware, treated and with BP controlled – concluded that, based on the solid evidence of large clinical trials, the efficacy of different drugs for the prevention of cardiovascular events is similar in males and females, and that there are no gender-specific suggestions. Our study was not intended to find possible gender differences, but to evaluate whether this possibility had been sufficiently investigated in the controlled clinical studies on which our knowledge and current treatment guidelines are based.

The extensive review of the literature we carried out shows that this has not always been done, and therefore useful information on gender differences may have been left out: this could prevent an effective personalization of the antihypertensive therapy.

Key messages

- Hypertension is an important risk factor for cardiovascular diseases.
- As stated in the ESC-ESH guidelines, the treatment of hypertension is associated with a significant reduction in all major cardiovascular events, irrespective of sex.
- It is not clear whether sufficient attention has been paid to gender differences in the studies that contributed to our knowledge of the hypertension treatment.
- This study shows that both sexes were almost equally represented in controlled clinical trials, but that the results were considered separately only in 21/33 of cases, and that very seldom the meta-analyses that combine the results of a large number of studies to gain enough power for subgroup analysis paid attention to gender.
- The extensive review of the literature we performed shows that not enough attention has been given to gender, and therefore useful information on gender differences may have been left out: this could prevent an effective personalization of the antihypertensive therapy.

References

1. Global health estimates 2016: death by cause, age, sex, by country and by region, 2000-2016. Geneva: World health organization; 2018 [Internet]. Available from: https://www.who.int/healthinfo/global_burden_disease/estimates/en/.
2. Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. *Curr Hypertens Rep.* 2013;15(3): 134-6.
3. Ramirez LA, Sullivan JC. Sex differences in hypertension: where we have been and where we are going. *Am J Hypertens.* 2018;31(12):1247-54.
4. Mills KT, Bundy JD, Kelly TN et al. Global disparities of hypertension prevalence and control. A systematic analysis of population-based studies from 90 countries. *Circulation.* 2016;134(6):441-50.
5. Ettehad D, Edmin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387: 957-67.
6. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J.* 2018;39:3021-104.

7. Turnbull F, Woodward M, Neal B et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. *Eur Heart J*. 2008;29(21):2669-80.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *Jama*. 1991; 265:3255-64.
9. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). *Lancet*. 1991;338:1281-5.
10. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet*. 1997;350:757-64.
11. UK Prospective Diabetes Study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317: 703-13.
12. Hansson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet*. 1998;51:1755-62.
13. Zanchetti A, Hansson L, Clement D et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? *J Hypertens*. 2003;21: 797-804.
14. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme-inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. *Lancet*. 1999;353:611-6.
15. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish trial in old patients with hypertension-2 study. *Lancet*. 1999;354:1751-6.
16. Brown MJ, Pamer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine Gits Study: intervention as a goal in hypertension treatment (INSIGHT). *Lancet*. 2000;356: 366-72.
17. Hedner T. Progress report on the Nordic Diltiazem Study (NORDIL): an outcome study in hypertensive patients. *Blood Press*. 1999;8:296-9.
18. Kjeldsen SE, Hedner T, Svyertsen JO et al. Influence of age, sex and blood pressure on the principal results of the Nordic Diltiazem (NORDIL) Study. *J Hypertens*. 2002;20(6): 1231-7.
19. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (SYST-CHINA) Collaborative Group. *Arch Intern Med*. 2000;160:211-20.
20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet*. 2001;358:1033-41.
21. Arima H, Chalmers J. PROGRESS: prevention of recurrent stroke. *J Clin Hypertens*. 2011;13:693-702.
22. ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *Jama*. 2002;288:2981-97.
23. Zanchetti A, Bond G, Henning M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double blind, long-term trial. *Circulation*. 2002;106:2422-7.
24. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003.
25. Os I, Franco V, Kjeldsen SE et al. Effects of losartan in women with hypertension and left ventricular hypertrophy. Results from the losartan intervention for endpoint reduction in hypertension study. *Hypertension*. 2008;51(4):1103-8.
26. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. *JAMA*. 2003;290:2805-16.
27. Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens*. 2003;21:875-86.
28. Trenkwalder P, Elmfeldt D, Hofman A et al. The Study on Cognition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients. *Blood Press*. 2005;14(1):31-7.
29. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004;363:2022-31.
30. Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. *J Hypertens*. 2006;24(11):2163-8.
31. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcome Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*. 2005;366:895-906.
32. Black HR, Elliott WJ, Grandits G et al. Principal results on the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA*. 2003;289:2073-82.
33. Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in chinese hypertensive patients. *J Hypertens*. 2005; 23:2157-72.
34. Williams B, Lacy PS, Thom SM et al. Differential impact of blood-pressure lowering drugs on central aortic pressure

- and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*. 2006; 113:1213-25.
35. Ninomya T, Perkovic V, de Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol*. 2009;20: 1813-21.
 36. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358:1547-59.
 37. Jamerson K, Weber MA, Bakris GL et al. Benazapril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008;359:2417-28.
 38. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358:1887-98.
 39. The ACCORD study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362(17):1575-85.
 40. Tsujimoto T, Kajio H. Benefit of intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control. *Hypertension*. 2018;72:323-30.
 41. Matsuzaki M, Ogihara T, Umemoto S et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *J Hypertens*. 2011;29:1649-59.
 42. Sandset EC, Bath PM, Boysen G et al. The angiotensin-receptor-blocker candesartan for treatment of acute stroke (SCAST): a randomised placebo-controlled, double-blind trial. *Lancet*. 2011;377:741-75.
 43. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012;367:2204-13.
 44. Anderson CS, Heeley E, Huang W et al. Rapid blood pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med*. 2013;368:2355-65.
 45. Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279-90.
 46. Ogihara T, Saruta T, Rakugi H et al. Combination therapy of hypertension in elderly; a subgroup analysis of the combination of Olmesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. *Hypertens Res*. 2015;38:89-96.
 47. Wright JT, Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103-16.
 48. Gueyffier F, Boutitie F, Boissel JP et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. *Ann Intern Med*. 1997;126:761-7.
 49. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665.
 50. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment. A meta-analysis of randomized comparative studies. *Hypertension*. 2009;54:1084-91.
 51. Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. *Heart*. 2014;100:317-23.
 52. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. *J Hypertens*. 2014;32(12):2285-95.
 53. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 2. Effects at different baseline and achieved blood pressure levels: overview and meta-analyses of randomized trials. *J Hypertens*. 2014;32(12):2296-304.
 54. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 3. Effects in patients at different levels of cardiovascular risk: overview and meta-analyses of randomized trials. *J Hypertens*. 2014;32(12):2305-14.
 55. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 4. Effects of various classes of antihypertensive drugs: overview and meta-analyses. *J Hypertens*. 2015;33(2):195-211.
 56. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension. 5. Head-to-head comparisons of various classes of antihypertensive drugs: overview and meta-analyses. *J Hypertens*. 2015;33(7):1321-41.
 57. Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet*. 2016;387: 435-43.
 58. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. *BMJ*. 2016;352:i717.
 59. Etehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387: 957-67.
 60. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure: meta-analyses of randomized trials. *J Hypertens*. 2016;34(3):373-84.
 61. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 7. Effects of more vs less intensive blood pressure lowering and different achieved blood pressure levels: updated overview and meta-analyses of randomized trials. *J Hypertens*. 2016;34(4):613-22.
 62. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension. 8. Outcome reductions vs discontinuations because of adverse drug events: meta-analyses of randomized trials. *J Hypertens*. 2016;34(8):1451-63.
 63. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension. 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. *J Hypertens*. 2016;34(10):1921-32.

64. Bangalore S, Toklu B, Gianos E et al. Optimal systolic blood pressure target after Sprint: insights from network meta-analysis of randomized trials. *Am J Med.* 2017;130:707-19.
65. Giorgini P, Sahebkar A, Stamerra CA et al. Comparison of clinical outcomes between genders following antihypertensive therapy: a meta-analysis. *Curr Med Chem.* 2017;24:2639-49.
66. Weiss J, Freeman M, Low A et al. Benefits and harms of intensive blood pressure treatments in adults aged 60 years or older. A systematic review and meta-analysis. *Ann Intern Med.* 2017;166:419-29.
67. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 10. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. *J Hypertens.* 2017;35(5):922-44.
68. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. *J Hypertens.* 2017;35(11):2138-49.
69. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. *J Hypertens.* 2017;35(11):2150-60.
70. Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels. A systematic review and meta-analysis. *JAMA Intern Med.* 2018;178(1):28-36.
71. Karmali KN, Lloyd-Jones DM, van der Leeuw J et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. *PLoS Med.* 2018;15(3):e1002538.
72. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. 13. Benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. *J Hypertens.* 2018;36(8):1622-36.
73. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. 14. Effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. *J Hypertens.* 2018;36(8):1637-47.
74. Murad MH, Larrea-Mantilla L, Haddad A et al. Antihypertensive agents in older adults: a systematic review and meta-analysis of randomized clinical trials. *J Clin Endocrinol Metab.* 2019;104:1575-84.
75. Muiesan ML, Salvetti M, Rosei CA, Paini A. Gender differences in antihypertensive treatment: myths or legends? *High Blood Press Cardiovasc Prev.* 2016;23(2):105-13.

Author contribution statement: all the Authors contributed equally to the design and conduct of the research, and to the writing and revising the final version of the article.

Conflict of interest statement: the Authors declare no conflicts of interest.

Correspondence to:
Enrico Strocchi
 Via Parmense 18
 47923 Rimini - RN, Italia
 email: enrico.strocchi52@gmail.com